Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK/PD study of ceftriamidine sodium in community-acquired bacterial pneumonia
ChiCTR2400086640Phase 2Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceftriamidine and cefathiamidine in community acquired pneumonia (CAP) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Pharmacokinetic evaluation index, Population pharmacokinetic index and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ceftriamidinecefathiamidine
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on ChiCTR2400086640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086640.